These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 3284555

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Variable and conserved neutralization antigens of human immunodeficiency virus.
    Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Lasky LA, Berman PW.
    Nature; ; 324(6097):572-5. PubMed ID: 2431324
    [Abstract] [Full Text] [Related]

  • 3. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
    Nara PL, Robey WG, Arthur LO, Asher DM, Wolff AV, Gibbs CJ, Gajdusek DC, Fischinger PJ.
    J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of human and simian immunodeficiency virus plaque and neutralization assays.
    McKeating JA, McKnight A, McIntosh K, Clapham PR, Mulder C, Weiss RA.
    J Gen Virol; 1989 Dec; 70 ( Pt 12)():3327-33. PubMed ID: 2575137
    [Abstract] [Full Text] [Related]

  • 5. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
    Rook AH, Lane HC, Folks T, McCoy S, Alter H, Fauci AS.
    J Immunol; 1987 Feb 15; 138(4):1064-7. PubMed ID: 3027168
    [Abstract] [Full Text] [Related]

  • 6. Sensitive assay for neutralizing antibodies against AIDS-related viruses (HTLV-III/LAV).
    Harada S, Purtilo DT, Koyanagi Y, Sonnabend J, Yamamoto N.
    J Immunol Methods; 1986 Sep 27; 92(2):177-81. PubMed ID: 3639115
    [Abstract] [Full Text] [Related]

  • 7. Clonal selection of human immunodeficiency virus (HIV): serological differences in the envelope antigens of the cloned viruses and HIV prototypes (HTLV-III B, LAV, and ARV).
    Harada S, Kobayashi N, Koyanagi Y, Yamamoto N.
    Virology; 1987 Jun 27; 158(2):447-51. PubMed ID: 2438845
    [Abstract] [Full Text] [Related]

  • 8. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.
    Harada S, Koyanagi Y, Yamamoto N.
    Science; 1985 Aug 09; 229(4713):563-6. PubMed ID: 2992081
    [Abstract] [Full Text] [Related]

  • 9. Neutralizing antibodies and the course of HIV-induced disease.
    Wendler I, Bienzle U, Hunsmann G.
    AIDS Res Hum Retroviruses; 1987 Aug 09; 3(2):157-63. PubMed ID: 3650100
    [Abstract] [Full Text] [Related]

  • 10. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S.
    Virology; 2006 Jun 20; 350(1):34-47. PubMed ID: 16616287
    [Abstract] [Full Text] [Related]

  • 11. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.
    Nara PL, Hatch WC, Dunlop NM, Robey WG, Arthur LO, Gonda MA, Fischinger PJ.
    AIDS Res Hum Retroviruses; 1987 Jun 20; 3(3):283-302. PubMed ID: 3481271
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135).
    Böttiger B, Karlsson A, Andreasson PA, Naucler A, Costa CM, Biberfeld G.
    AIDS Res Hum Retroviruses; 1989 Oct 20; 5(5):525-33. PubMed ID: 2590556
    [Abstract] [Full Text] [Related]

  • 14. In vitro generation of an HTLV-III variant by neutralizing antibody.
    Robert-Guroff M, Reitz MS, Robey WG, Gallo RC.
    J Immunol; 1986 Nov 15; 137(10):3306-9. PubMed ID: 3639908
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Different HTLV-I neutralization patterns among sera of patients infected with cosmopolitan HTLV-I.
    Blanchard S, Astier-Gin T, Moynet D, Edouard E, Guillemain B.
    Virology; 1998 May 25; 245(1):90-8. PubMed ID: 9614870
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tumor promoter, TPA, enhances replication of HTLV-III/LAV.
    Harada S, Koyanagi Y, Nakashima H, Kobayashi N, Yamamoto N.
    Virology; 1986 Oct 30; 154(2):249-58. PubMed ID: 3639669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.